Cerus Corp CERS

Morningstar Rating
$2.28 −0.04 (1.72%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

CERS is trading at a LOCK|^D@nQ premium.
Price
$2.28
Fair Value
LOCK|v^kGC%
Uncertainty
LOCK|kg
1-Star Price
LOCK|Yx>Wd^
5-Star Price
LOCK|L@&gjj
Economic Moat
LOCK|S$L
Capital Allocation
—

News

Trading Information

Previous Close Price
$2.32
Day Range
$2.26–2.37
52-Week Range
$1.38–3.47
Bid/Ask
$2.30 / $2.37
Shares Outstanding
201.52M
Market Cap
$459.48M
Volume/Avg
2M / 2M

Key Statistics

Price/Earnings (Normalized)
44.37
Price/Sales
2.04
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Small Core
Total Number of Employees
345

Valuation

Metric
CERS
Price/Earnings (Normalized)
44.37
Price/Book Value
6.67
Price/Sales
2.04
Price/Cash Flow
24.93
Price/Earnings
CERS

Financial Strength

Metric
CERS
Quick Ratio
1.02
Current Ratio
1.83
Interest Coverage
0.16
Quick Ratio
CERS

Profitability

Metric
CERS
Return on Assets (Normalized)
4.26%
Return on Equity (Normalized)
14.41%
Return on Invested Capital (Normalized)
9.64%
Return on Assets
CERS

Medical Devices Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Abbott Laboratories
ABT
LOCK|t<#VBBLOCK|?@^S$169B
Medtronic PLC
MDT
LOCK|@%XPQKfLOCK|#PTP$110B
Stryker Corp
SYK
LOCK|Z#%#b@PXLOCK|N?$106B
Boston Scientific Corp
BSX
LOCK|Z>@?J@LOCK|lWhn?$62B
Edwards Lifesciences Corp
EW
LOCK|%!QWjGvLOCK|$Ngm$49B
DexCom Inc
DXCM
LOCK|#ck#^$<LOCK|&>Y^L$32B
GE HealthCare Technologies Inc Common Stock
GEHC
LOCK|gY&QK$YLOCK|Jfg$29B
Koninklijke Philips NV ADR
PHG
LOCK|dmLOCK|Hm#$23B
Steris PLC
STE
LOCK|Qcs><P^LOCK|z?P?P$20B
Zimmer Biomet Holdings Inc
ZBH
LOCK|^lNl!xcLOCK|Bn$17B

Sponsor Center